Debt-to-equity of Crinetics Pharmaceuticals, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Crinetics Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Crinetics Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 9.5%, a 28% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Crinetics Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 9.5% -3.8% -28% 30 Sep 2025
Q2 2025 9.6% -4.7% -33% 30 Jun 2025
Q1 2025 10% -5% -33% 31 Mar 2025
Q4 2024 11% -5.3% -33% 31 Dec 2024
Q3 2024 13% -1.2% -8.3% 30 Sep 2024
Q2 2024 14% +2.4% +21% 30 Jun 2024
Q1 2024 15% +4.6% +44% 31 Mar 2024
Q4 2023 16% +6.2% +63% 31 Dec 2023
Q3 2023 14% +5.8% +68% 30 Sep 2023
Q2 2023 12% +3.5% +43% 30 Jun 2023
Q1 2023 10% +2.6% +33% 31 Mar 2023
Q4 2022 10% +2.6% +36% 31 Dec 2022
Q3 2022 8.6% +0.24% +2.9% 30 Sep 2022
Q2 2022 8.3% +0.2% +2.5% 30 Jun 2022
Q1 2022 7.8% -0.09% -1.1% 31 Mar 2022
Q4 2021 7.4% -1.3% -15% 31 Dec 2021
Q3 2021 8.4% -0.73% -8% 30 Sep 2021
Q2 2021 8.1% -2% -19% 30 Jun 2021
Q1 2021 7.9% -3.1% -28% 31 Mar 2021
Q4 2020 8.6% -1.3% -13% 31 Dec 2020
Q3 2020 9.1% +0.29% +3.3% 30 Sep 2020
Q2 2020 10% +2.4% +31% 30 Jun 2020
Q1 2020 11% +1.9% +20% 31 Mar 2020
Q4 2019 9.9% 31 Dec 2019
Q3 2019 8.8% 30 Sep 2019
Q2 2019 7.7% 30 Jun 2019
Q1 2019 9.2% 31 Mar 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.